← Eichor
Study identifier: NCT06493799 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Condition: Chronic Liver Disease  ·  Sponsor: Green Cross Wellbeing

PhasePhase 3
Planned participants226
Who can joinAll sexes, 19 Years to 70 Years
Healthy volunteersNo

About this study

Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)

This description comes directly from the study's public registry record.

Talk to the study team

Yeongmin Kwon  ·  +82-70-8892-7881  ·  ymkwon@gccorp.com

Always discuss trial participation with your own doctor first.

Locations (1)

GC wellbeingYongin-si, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06493799